Pharmaceutics (Jan 2024)

PEG–Lipid–PLGA Hybrid Particles for Targeted Delivery of Anti-Inflammatory Drugs

  • Jana Ismail,
  • Lea C. Klepsch,
  • Philipp Dahlke,
  • Ekaterina Tsarenko,
  • Antje Vollrath,
  • David Pretzel,
  • Paul M. Jordan,
  • Kourosh Rezaei,
  • Justyna A. Czaplewska,
  • Steffi Stumpf,
  • Baerbel Beringer-Siemers,
  • Ivo Nischang,
  • Stephanie Hoeppener,
  • Oliver Werz,
  • Ulrich S. Schubert

DOI
https://doi.org/10.3390/pharmaceutics16020187
Journal volume & issue
Vol. 16, no. 2
p. 187

Abstract

Read online

Hybrid nanoparticles (HNPs) were designed by combining a PLGA core with a lipid shell that incorporated PEG–Lipid conjugates with various functionalities (-RGD, -cRGD, -NH2, and -COOH) to create targeted drug delivery systems. Loaded with a neutral lipid orange dye, the HNPs were extensively characterized using various techniques and investigated for their uptake in human monocyte-derived macrophages (MDMs) using FC and CLSM. Moreover, the best-performing HNPs (i.e., HNP-COOH and HNP-RGD as well as HNP-RGD/COOH mixed) were loaded with the anti-inflammatory drug BRP-201 and prepared in two size ranges (dH ~140 nm and dH ~250 nm). The HNPs were examined further for their stability, degradation, MDM uptake, and drug delivery efficiency by studying the inhibition of 5-lipoxygenase (5-LOX) product formation, whereby HNP-COOH and HNP-RGD both exhibited superior uptake, and the HNP-COOH/RGD (2:1) displayed the highest inhibition.

Keywords